Results 281 to 290 of about 8,266,387 (310)

Plying potency assays for immunotherapy of solid tumors. [PDF]

Front Immunol
Burns JS, Gjeta R, Lesný P, Vives J.
europepmc   +1 more source

Engineered Peptide Self-Assembled Nanofibers for Enhanced STING Activation: A Promising Nanodelivery Platform for Immunotherapy of Pediatric Solid Tumors. [PDF]

Adv Sci (Weinh)
He Y, Lu X, Yang CQ, Zhang R, Wan B, Ni X, Mei D.   +6 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

A Peritumorally Injected Immunomodulating Adjuvant Elicits Robust and Safe Metalloimmunotherapy against Solid Tumors

Advances in Materials, 2022
Clinical immunotherapy of solid tumors elicits durable responses only in a minority of patients, largely due to the highly immunosuppressive tumor microenvironment (TME).
Ling-Xiao Zhang, Jing Zhao, Xi Hu, Chenhan Wang, Yingbo Jia, Chaojie Zhu, Shangzhi Xie, Jiyoung Lee, Fang-Yuan Li, D. Ling   +9 more
semanticscholar   +1 more source

CAR-T therapy in solid tumors.

Cancer Cell
While chimeric antigen receptor (CAR) T cell therapy has shown great success in hematologic malignancies, the effectiveness in solid tumors has been limited by several factors, including antigenic heterogeneity and the immunosuppressive nature of the ...
Bing Du, Juliang Qin, Bo Lin, Jiqin Zhang, Dali Li, Mingyao Liu   +5 more
semanticscholar   +1 more source

CAR-T cells in solid tumors: Challenges and breakthroughs

Cell Reports Medicine
Summary Chimeric antigen receptor (CAR)-T cell therapy has revolutionized the treatment of hematologic malignancies, but its efficacy in solid tumors is limited by several challenges.
Giulia Escobar, Trisha R. Berger, Marcela V. Maus   +2 more
semanticscholar   +1 more source

Chimeric STAR receptors using TCR machinery mediate robust responses against solid tumors

Science Translational Medicine, 2021
T cells engineered with synthetic receptors that integrate components of T cell and B cell receptors show efficacy against solid tumors in mice. The STAR of the show Chimeric antigen receptor (CAR) T cells have revolutionized treatment for hematological ...
Yue Liu, Guangna Liu, Jiasheng Wang, Zhe-yu Zheng, Le-Mei Jia, Wei Rui, Daosheng Huang, Zhi-Xiao Zhou, Liqun Zhou, Xin Wu, Song Lin, Xue-Qiang Zhao, Xin Lin   +12 more
semanticscholar   +1 more source

An RNA vaccine drives expansion and efficacy of claudin-CAR-T cells against solid tumors

Science, 2020
A one-two, CAR-T cell punch Chimeric antigen receptor (CAR)–T cells have been clinically effective in killing certain hematological malignancies, but achieving long-term patient responses for solid tumors remains a challenge. Reinhard et al.
Katharina Reinhard, B. Rengstl, P. Oehm, K. Michel, Arne Billmeier, Nina Hayduk, Oliver J. Klein, Kathrin Kuna, Yasmina Ouchan, S. Wöll, E. Christ, David Weber, Martin Suchan, Thomas Bukur, M. Birtel, V. Jahndel, Karolina Mróz, K. Hobohm, L. Kranz, M. Diken, K. Kühlcke, O. Türeci, U. Şahin   +22 more
semanticscholar   +1 more source

Circulating tumor DNA in advanced solid tumors: Clinical relevance and future directions

Ca-A Cancer Journal for Clinicians, 2021
Heather Parsons, Atish D. Choudhury, Michael L Cheng   +2 more
exaly